カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のゲノム編集市場2023-2030：技術別（CRISPR、ZFN、TALEN）、送達方法別（エクスビボ、インビボ）、用途別、モード別、エンドユーザー別、地域別

【英語タイトル】Genome Editing Market Size, Share & Trends Analysis Report By Technology (CRISPR, ZFN, TALEN), By Delivery Method (Ex-vivo, In-vivo), By Application, By Mode, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN050）・商品コード：GRV23JUN050
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月15日
・ページ数：180
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界のゲノム編集市場規模が、予測期間中（2023年～2030年）に年平均17.8％増加し、2030年までに249.9億ドルへ達すると見込まれています。本調査書では、ゲノム編集の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、技術別（CRISPR/Cas9、TALEN/メガTAL、ZFN、メガヌクレアーゼ、その他）分析、送達方法別（エクスビボ、インビボ）分析、用途別（遺伝子工学、臨床）分析、エンドユーザー別（バイオテクノロジー・医薬品企業、学術・政府研究機関、契約研究機関（CRO））分析、地域別（北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Merck KGaA、Cibus、Recombinetics, Inc、Sangamo、Editas Medicine、Precision Biosciences、CRISPR THERAPEUTICS、Intellia Therapeutics, Inc.、Caribou Biosciences, Inc、Cellectis、AstraZeneca、Takara Bio Inc.、Horizon Discovery Group plcなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界ゲノム編集の市場規模：技術別
- CRISPR/Cas9における市場規模
- TALEN/メガTALにおける市場規模
- ZFNにおける市場規模
- メガヌクレアーゼにおける市場規模
- その他技術における市場規模
・世界ゲノム編集の市場規模：送達方法別
- エクスビボにおける市場規模
- インビボにおける市場規模
・世界ゲノム編集の市場規模：用途別
- 遺伝子工学における市場規模
- 臨床における市場規模
・世界ゲノム編集の市場規模：エンドユーザー別
- バイオテクノロジー・医薬品企業における市場規模
- 学術・政府研究機関における市場規模
- 契約研究機関（CRO）における市場規模
・世界ゲノム編集の市場規模：地域別
- 北米のゲノム編集市場規模
- ヨーロッパのゲノム編集市場規模
- アジア太平洋のゲノム編集市場規模
- 中南米のゲノム編集市場規模
- 中東・アフリカのゲノム編集市場規模
・競争状況

ゲノム編集市場の成長と動向

Grand View Research, Incの最新レポートによると、世界のゲノム編集市場規模は2030年までに249億9000万米ドルに達し、2023年から2030年までのCAGRは17.8％を示す見込みです。ゲノム編集技術の更なる進化、ゲノミクス産業への資金調達と投資の増加、遺伝性疾患の有病率の増加、改善された治療と療法の必要性が、収益成長を促進する主な要因です。

ゲノム編集技術の進化は、市場の収益成長を促進する1つの要因です。CRISPR-Cas13、プライム編集、塩基編集などを含む新しく高度なゲノム編集法の強化によって最も効果的で正確な遺伝子編集が可能になり、これにより学術的・医療的な文脈でより頻繁に使用されるゲノム編集法が生まれます。例えば、2020年1月、ERS GenomicsとNew England BiolabはCRISPR遺伝子改変ツールと試薬の開発と商業化のために協力しました。

治療研究への遺伝子改変ツールの応用が進むにつれ、臨床試験に入る先端治療薬の数が増加しています。さらに、新しい遺伝子改変システムの実装を進めるための人工知能の使用は、技術開発者にとって大きな可能性を示しています。このことは、予測可能な将来において、収益獲得に大きく有利に働くと予想されます。研究コミュニティは、様々な慢性疾患に対する迅速なスクリーニング・ソリューションの可能性として、CRISPRのような遺伝子改変装置の可能性を探っています。このような研究プログラムは、今後数年間、ゲノム編集市場に利益をもたらす可能性が高いといえます。

ゲノム編集市場レポートハイライト

– 技術別では、CRISPR/Cas9セグメントが2022年に42.9%の最高シェアを占めました。これは、標的遺伝子破壊などの利点によりCRISPRの利用が増加しているためです。

– 2022年の送達方法セグメントでは、生体外が52.6%と圧倒的なシェアを占めました。この支配的なシェアは、DNA改変においてこのモデルが提供する高い制御性が拡大していることに起因しています。

– 遺伝子工学分野は、遺伝子治療の臨床試験の増加により、用途別で世界市場の首位に立ちました。

– エンドユーザー別では、バイオテクノロジーおよび製薬企業セグメントが2022年に51.2％の主要シェアを獲得しました。

– 受託サービスプロバイダーが提供する費用対効果の高いサービスにより、受託ベースのセグメントが2022年の市場を独占しました。

– 北米は2022年に47.9%の圧倒的シェアを占めました。その主な理由は、同地域で遺伝子治療や幹細胞治療の臨床試験が数多く実施されていることに加え、先端治療開発のための強力な研究や商業基盤が存在することです。

– 主な企業としては、Merck KGaA、Cibus、Recombinetics, Inc.、Sangamo、Editas Medicine、Precision Biosciences、CRISPR Therapeutics、Intellia Therapeutics, Inc.、Caribou Biosciences, Inc.、Cellectis S.A.、AstraZeneca、Takara Bio USA、Horizon Discovery Group plc、Integrated DNA Technologies, Inc.、Egenesis Inc.、GenScript、New England Biolabs、OriGene Technologies, Inc.などが挙げられます。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Success in pre-clinical models drives demands for genome editing therapeutics
3.4.2. Rising competition amongst market participants for business development
3.4.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
3.4.4. Increasing demand for synthetic genes and genetically modified organisms
3.4.5. Technological advancements in gene editing technologies
3.4.6. Rising adoption in agricultural biotechnology
3.5. Market Restraint Analysis
3.5.1. Challenges concerning clinical translation
3.5.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
3.5.3. Off-target effects of CRISPR technology
3.6. Business Environment Analysis
3.7. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.8. Porter’s Five Forces Analysis
3.9. Genome Editing Technologies: Pipeline Analysis
3.9.1. Sangamo
3.9.2. Cellectis
3.9.3. Calyxt
3.9.4. bluebird bio
3.9.5. Editas Medicine
3.9.6. Intellia Therapeutics, Inc.
3.9.7. CRISPR Therapeutics
3.9.8. Precision Biosciences
3.9.9. Precision Biosciences (Non-medical domain)
3.9.10. Caribou Biosciences
3.9.11. Cibus
3.9.12. Recombinetics, Inc
3.10. Intellectual Property
3.11. Regulatory Issues
3.11.1. Orphan diseases
3.11.2. Germline editing
3.11.3. Safety issues
3.12. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Genome Editing Market: Technology Movement Analysis
4.2. Genome EditingTechnology Comparison
4.3. (CRISPR)/Cas9
4.3.1. Global (CRISPR)/Cas9 market, 2018 – 2030 (USD Million)
4.4. TALENs/MegaTALs
4.4.1. Global TALENs/MegaTALs market, 2018 – 2030 (USD Million)
4.5. ZFN
4.5.1. Global ZFN market, 2018 – 2030 (USD Million)
4.6. Meganucleases
4.6.1. Global Meganucleases market, 2018 – 2030 (USD Million)
4.7. Other Technologies
4.7.1. Global other technologies market, 2018 – 2030 (USD Million)
Chapter 5. Delivery Method Business Analysis
5.1. Genome Editing Market: Delivery Method Movement Analysis
5.1.1. Comparison of Delivery Methods
5.1.1.1. Viral delivery
5.1.1.1.1. AAV (Adeno Associated Virus)
5.1.1.1.2. IDLV (Integrase Deficient Lentivirus).
5.1.1.2. Non-viral delivery
5.1.1.2.1. Lipid Mediated
5.1.1.2.2. Electroporation
5.2. Ex-vivo
5.2.1. Global ex-vivo delivery market, 2018 – 2030 (USD Million)
5.3. In-vivo
5.3.1. Global in-vivo delivery market, 2018 – 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Genome Editing Market: Application Movement Analysis
6.2. Genetic Engineering
6.2.1. Genetic Engineering Market, 2018 – 2030 (USD Million)
6.2.1.1. Cell line engineering
6.2.1.1.1. Cell line engineering Market, 2018 – 2030 (USD Million)
6.2.1.2. Animal genetic engineering
6.2.1.2.1. Animal genetic engineering Market, 2018 – 2030 (USD Million)
6.2.1.3. Plant genetic engineering
6.2.1.3.1. Plant genetic engineering Market, 2018 – 2030 (USD Million)
6.2.1.4. Others
6.2.1.4.1. Global others market, 2018 – 2030 (USD Million)
6.3. Clinical Applications
6.3.1. Market for clinical applications, 2018 – 2030 (USD Million)
6.3.1.1. Diagnostics
6.3.1.1.1. Market for diagnostics applications, 2018 – 2030 (USD Million)
6.3.1.2. Therapy Development
6.3.1.2.1. Market for therapy development applications, 2018 – 2030 (USD Million)
Chapter 7. End-User Business Analysis
7.1. Genome Editing Market: End-User Movement Analysis
7.2. Biotechnology & Pharmaceutical Companies
7.2.1. Biotechnology & Pharmaceutical Companies Market, 2018 – 2030 (USD Million)
7.3. Academic & Government Research Institutes
7.3.1. Academic & Government Research Institutes Market, 2018 – 2030 (USD Million)
7.4. Contract Research Organizations (CROs)
7.4.1. Contract Research Organizations (CROs) Market, 2018 – 2030 (USD Million)
Chapter 8. Genome Editing Market: Mode Business Analysis
8.1. Genome Editing Market: Mode Movement Analysis
8.2. In-house
8.2.1. In-house Market, 2018 – 2030 (USD Million)
8.3. Contract
8.3.1. Contract Market, 2018 – 2030 (USD Million)
Chapter 9. Regional Business Analysis
9.1. Genome Editing Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. SWOT Analysis
9.2.2. North America genome editing market, 2018 – 2030 (USD Million)
9.2.3. U.S.
9.2.3.1. Key Country Dynamics
9.2.3.2. Competitive Scenario
9.2.3.3. Regulatory Framework
9.2.3.4. Target Disease Prevalence
9.2.3.5. U.S. genome editing market, 2018 – 2030 (USD Million)
9.2.4. Canada
9.2.4.1. Key Country Dynamics
9.2.4.2. Competitive Scenario
9.2.4.3. Regulatory Framework
9.2.4.4. Target Disease Prevalence
9.2.4.5. Canada genome editing market, 2018 – 2030 (USD Million)
9.3. Europe
9.3.1. SWOT Analysis
9.3.2. Europe genome editing market, 2018 – 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Framework
9.3.3.4. Target Disease Prevalence
9.3.3.5. Germany genome editing market, 2018 – 2030 (USD Million)
9.3.4. UK
9.3.4.1. Key Country Dynamics
9.3.4.2. Competitive Scenario
9.3.4.3. Regulatory Framework
9.3.4.4. Target Disease Prevalence
9.3.4.5. UK genome editing market, 2018 – 2030 (USD Million)
9.3.5. France
9.3.5.1. Key Country Dynamics
9.3.5.2. Competitive Scenario
9.3.5.3. Regulatory Framework
9.3.5.4. Target Disease Prevalence
9.3.5.5. France genome editing market, 2018 – 2030 (USD Million)
9.3.6. Italy
9.3.6.1. Key Country Dynamics
9.3.6.2. Competitive Scenario
9.3.6.3. Regulatory Framework
9.3.6.4. Target Disease Prevalence
9.3.6.5. Italy genome editing market, 2018 – 2030 (USD Million)
9.3.7. Spain
9.3.7.1. Key Country Dynamics
9.3.7.2. Competitive Scenario
9.3.7.3. Regulatory Framework
9.3.7.4. Target Disease Prevalence
9.3.7.5. Spain genome editing market, 2018 – 2030 (USD Million)
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Competitive Scenario
9.3.8.3. Regulatory Framework
9.3.8.4. Target Disease Prevalence
9.3.8.5. Denmark genome editing market, 2018 – 2030 (USD Million)
9.3.9. Sweden
9.3.9.1. Key Country Dynamics
9.3.9.2. Competitive Scenario
9.3.9.3. Regulatory Framework
9.3.9.4. Target Disease Prevalence
9.3.9.5. Sweden genome editing market, 2018 – 2030 (USD Million)
9.3.10. Norway
9.3.10.1. Key Country Dynamics
9.3.10.2. Competitive Scenario
9.3.10.3. Regulatory Framework
9.3.10.4. Target Disease Prevalence
9.3.10.5. Norway genome editing market, 2018 – 2030 (USD Million)
9.4. Asia Pacific
9.4.1. SWOT Analysis
9.4.2. Asia Pacific genome editing market, 2018 – 2030 (USD Million)
9.4.3. Japan
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Framework
9.4.3.4. Target Disease Prevalence
9.4.3.5. Japan genome editing market, 2018 – 2030 (USD Million)
9.4.4. China
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Framework
9.4.4.4. Target Disease Prevalence
9.4.4.5. China genome editing market, 2018 – 2030 (USD Million)
9.4.5. India
9.4.5.1. Key Country Dynamics
9.4.5.2. Competitive Scenario
9.4.5.3. Regulatory Framework
9.4.5.4. Target Disease Prevalence
9.4.5.5. India genome editing market, 2018 – 2030 (USD Million)
9.4.6. South Korea
9.4.6.1. Key Country Dynamics
9.4.6.2. Competitive Scenario
9.4.6.3. Regulatory Framework
9.4.6.4. Target Disease Prevalence
9.4.6.5. South Korea genome editing market, 2018 – 2030 (USD Million)
9.4.7. Australia
9.4.7.1. Key Country Dynamics
9.4.7.2. Competitive Scenario
9.4.7.3. Regulatory Framework
9.4.7.4. Target Disease Prevalence
9.4.7.5. Australia genome editing market, 2018 – 2030 (USD Million)
9.4.8. Thailand
9.4.8.1. Key Country Dynamics
9.4.8.2. Competitive Scenario
9.4.8.3. Regulatory Framework
9.4.8.4. Target Disease Prevalence
9.4.8.5. Thailand genome editing market, 2018 – 2030 (USD Million)
9.5. Latin America
9.5.1. SWOT Analysis
9.5.2. Latin America genome editing market, 2018 – 2030 (USD Million)
9.5.3. Brazil
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Framework
9.5.3.4. Target Disease Prevalence
9.5.3.5. Brazil genome editing market, 2018 – 2030 (USD Million)
9.5.4. Mexico
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Framework
9.5.4.4. Target Disease Prevalence
9.5.4.5. Mexico genome editing market, 2018 – 2030 (USD Million)
9.5.5. Argentina
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Framework
9.5.5.4. Target Disease Prevalence
9.5.5.5. Argentina genome editing market, 2018 – 2030 (USD Million)
9.6. MEA
9.6.1. SWOT Analysis
9.6.2. MEA genome editing market, 2018 – 2030 (USD Million)
9.6.3. South Africa
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Framework
9.6.3.4. Target Disease Prevalence
9.6.3.5. South Africa genome editing market, 2018 – 2030 (USD Million)
9.6.4. Saudi Arabia
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Framework
9.6.4.4. Target Disease Prevalence
9.6.4.5. Saudi Arabia genome editing market, 2018 – 2030 (USD Million)
9.6.5. UAE
9.6.5.1. Key Country Dynamics
9.6.5.2. Competitive Scenario
9.6.5.3. Regulatory Framework
9.6.5.4. Target Disease Prevalence
9.6.5.5. UAE genome editing market, 2018 – 2030 (USD Million)
9.6.6. Kuwait
9.6.6.1. Key Country Dynamics
9.6.6.2. Competitive Scenario
9.6.6.3. Regulatory Framework
9.6.6.4. Target Disease Prevalence
9.6.6.5. Kuwait genome editing market, 2018 – 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Profiles/Listing
10.3.1. Merck KGaA
10.3.1.1. Overview
10.3.1.1.1. Sigma-Aldrich Co. LLC
10.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.1.3. Product Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Cibus
10.3.2.1. Overview
10.3.2.1.1. Nucelis
10.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.2.3. Product Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Recombinetics, Inc
10.3.3.1. Overview
10.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.3.3. Product Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. Sangamo
10.3.4.1. Overview
10.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.4.3. Product Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. Editas Medicine
10.3.5.1. Overview
10.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.5.3. Product Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Precision Biosciences
10.3.6.1. Overview
10.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.6.3. Product Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. CRISPR THERAPEUTICS
10.3.7.1. Overview
10.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.7.3. Product Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. Intellia Therapeutics, Inc.
10.3.8.1. Overview
10.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.8.3. Product Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Caribou Biosciences, Inc
10.3.9.1. Overview
10.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.9.3. Product Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Cellectis
10.3.10.1. Overview
10.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.10.3. Product Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. AstraZeneca
10.3.11.1. Overview
10.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.11.3. Product Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. Takara Bio Inc.
10.3.12.1. Overview
10.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.12.3. Product Benchmarking
10.3.12.4. Strategic Initiatives
10.3.13. Horizon Discovery Group plc
10.3.13.1. Overview
10.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.13.3. Product Benchmarking
10.3.13.4. Strategic Initiatives
10.3.14. Integrated DNA Technologies, Inc.
10.3.14.1. Overview
10.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.14.3. Product Benchmarking
10.3.14.4. Strategic Initiatives
10.3.15. Transposagen Biopharmaceuticals, Inc.
10.3.15.1. Overview
10.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.15.3. Product Benchmarking
10.3.15.4. Strategic Initiatives
10.3.16. GenScript
10.3.16.1. Overview
10.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.16.3. Product Benchmarking
10.3.16.4. Strategic Initiatives
10.3.17. New England Biolabs
10.3.17.1. Overview
10.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.17.3. Product Benchmarking
10.3.17.4. Strategic Initiatives
10.3.18. OriGene Technologies, Inc.
10.3.18.1. Overview
10.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.18.3. Product Benchmarking
10.3.18.4. Strategic Initiatives
10.3.19. bluebird bio, Inc.
10.3.19.1. Overview
10.3.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.19.3. Product Benchmarking
10.3.19.4. Strategic Initiatives
10.3.20. Lonza
10.3.20.1. Overview
10.3.20.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.20.3. Product Benchmarking
10.3.20.4. Strategic Initiatives
10.3.21. Thermo Fisher Scientific, Inc.
10.3.21.1. Overview
10.3.21.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.3.21.3. Product Benchmarking
10.3.21.4. Strategic Initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 Global genome editing market, by technology, 2018 - 2030 (USD Million)
Table 3 Global genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 4 Global genome editing market, by application, 2018 - 2030 (USD Million)
Table 5 Global genome editing market, by mode, 2018 - 2030 (USD Million)
Table 6 Global genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 7 Global genome editing market, by region, 2018 - 2030 (USD Million)
Table 8 North America genome editing market, by country, 2018 - 2030 (USD Million)
Table 9 North America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 10 North America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 11 North America genome editing market, by application, 2018 - 2030 (USD Million)
Table 12 North America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 13 North America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 14 U.S. genome editing market, by technology, 2018 - 2030 (USD Million)
Table 15 U.S. genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 16 U.S. genome editing market, by application, 2018 - 2030 (USD Million)
Table 17 U.S. genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 18 U.S. genome editing market, by mode, 2018 - 2030 (USD Million)
Table 19 Canada genome editing market, by technology, 2018 - 2030 (USD Million)
Table 20 Canada genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 21 Canada genome editing market, by application, 2018 - 2030 (USD Million)
Table 22 Canada genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 23 Canada genome editing market, by mode, 2018 - 2030 (USD Million)
Table 24 Europe genome editing market, by country, 2018 - 2030 (USD Million)
Table 25 Europe genome editing market, by technology, 2018 - 2030 (USD Million)
Table 26 Europe genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 27 Europe genome editing market, by application, 2018 - 2030 (USD Million)
Table 28 Europe genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 29 Europe genome editing market, by mode, 2018 - 2030 (USD Million)
Table 30 Germany genome editing market, by technology, 2018 - 2030 (USD Million)
Table 31 Germany genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 32 Germany genome editing market, by application, 2018 - 2030 (USD Million)
Table 33 Germany genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 34 Germany genome editing market, by mode, 2018 - 2030 (USD Million)
Table 35 UK genome editing market, by technology, 2018 - 2030 (USD Million)
Table 36 UK genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 37 UK genome editing market, by application, 2018 - 2030 (USD Million)
Table 38 UK genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 39 UK genome editing market, by mode, 2018 - 2030 (USD Million)
Table 40 France genome editing market, by technology, 2018 - 2030 (USD Million)
Table 41 France genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 42 France genome editing market, by application, 2018 - 2030 (USD Million)
Table 43 France genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 44 France genome editing market, by mode, 2018 - 2030 (USD Million)
Table 45 Italy genome editing market, by technology, 2018 - 2030 (USD Million)
Table 46 Italy genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 47 Italy genome editing market, by application, 2018 - 2030 (USD Million)
Table 48 Italy genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 49 Italy genome editing market, by mode, 2018 - 2030 (USD Million)
Table 50 Spain genome editing market, by technology, 2018 - 2030 (USD Million)
Table 51 Spain genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 52 Spain genome editing market, by application, 2018 - 2030 (USD Million)
Table 53 Spain genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 54 Spain genome editing market, by mode, 2018 - 2030 (USD Million)
Table 55 Denmark genome editing market, by technology, 2018 - 2030 (USD Million)
Table 56 Denmark genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 57 Denmark genome editing market, by application, 2018 - 2030 (USD Million)
Table 58 Denmark genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 59 Denmark genome editing market, by mode, 2018 - 2030 (USD Million)
Table 60 Sweden genome editing market, by technology, 2018 - 2030 (USD Million)
Table 61 Sweden genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 62 Sweden genome editing market, by application, 2018 - 2030 (USD Million)
Table 63 Sweden genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 64 Sweden genome editing market, by mode, 2018 - 2030 (USD Million)
Table 65 Norway genome editing market, by technology, 2018 - 2030 (USD Million)
Table 66 Norway genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 67 Norway genome editing market, by application, 2018 - 2030 (USD Million)
Table 68 Norway genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 69 Norway genome editing market, by mode, 2018 - 2030 (USD Million)
Table 70 Asia Pacific genome editing market, by country, 2018 - 2030 (USD Million)
Table 71 Asia Pacific genome editing market, by technology, 2018 - 2030 (USD Million)
Table 72 Asia Pacific genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 73 Asia Pacific genome editing market, by application, 2018 - 2030 (USD Million)
Table 74 Asia Pacific genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 75 Asia Pacific genome editing market, by mode, 2018 - 2030 (USD Million)
Table 76 China genome editing market, by technology, 2018 - 2030 (USD Million)
Table 77 China genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 78 China genome editing market, by application, 2018 - 2030 (USD Million)
Table 79 China genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 80 China genome editing market, by mode, 2018 - 2030 (USD Million)
Table 81 Japan genome editing market, by technology, 2018 - 2030 (USD Million)
Table 82 Japan genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 83 Japan genome editing market, by application, 2018 - 2030 (USD Million)
Table 84 Japan genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 85 Japan genome editing market, by mode, 2018 - 2030 (USD Million)
Table 86 India genome editing market, by technology, 2018 - 2030 (USD Million)
Table 87 India genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 88 India genome editing market, by application, 2018 - 2030 (USD Million)
Table 89 India genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 90 India genome editing market, by mode, 2018 - 2030 (USD Million)
Table 91 South Korea genome editing market, by technology, 2018 - 2030 (USD Million)
Table 92 South Korea genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 93 South Korea genome editing market, by application, 2018 - 2030 (USD Million)
Table 94 South Korea genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 95 South Korea genome editing market, by mode, 2018 - 2030 (USD Million)
Table 96 Australia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 97 Australia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 98 Australia genome editing market, by application, 2018 - 2030 (USD Million)
Table 99 Australia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 100 Australia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 101 Thailand genome editing market, by technology, 2018 - 2030 (USD Million)
Table 102 Thailand genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 103 Thailand genome editing market, by application, 2018 - 2030 (USD Million)
Table 104 Thailand genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 105 Thailand genome editing market, by mode, 2018 - 2030 (USD Million)
Table 106 Latin America genome editing market, by country, 2018 - 2030 (USD Million)
Table 107 Latin America genome editing market, by technology, 2018 - 2030 (USD Million)
Table 108 Latin America genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 109 Latin America genome editing market, by application, 2018 - 2030 (USD Million)
Table 110 Latin America genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 111 Latin America genome editing market, by mode, 2018 - 2030 (USD Million)
Table 112 Brazil genome editing market, by technology, 2018 - 2030 (USD Million)
Table 113 Brazil genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 114 Brazil genome editing market, by application, 2018 - 2030 (USD Million)
Table 115 Brazil genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 116 Brazil genome editing market, by mode, 2018 - 2030 (USD Million)
Table 117 Mexico genome editing market, by technology, 2018 - 2030 (USD Million)
Table 118 Mexico genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 119 Mexico genome editing market, by application, 2018 - 2030 (USD Million)
Table 120 Mexico genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 121 Mexico genome editing market, by mode, 2018 - 2030 (USD Million)
Table 122 Argentina genome editing market, by technology, 2018 - 2030 (USD Million)
Table 123 Argentina genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 124 Argentina genome editing market, by application, 2018 - 2030 (USD Million)
Table 125 Argentina genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 126 Argentina genome editing market, by mode, 2018 - 2030 (USD Million)
Table 127 Middle East & Africa genome editing market, by country, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 133 South Africa genome editing market, by technology, 2018 - 2030 (USD Million)
Table 134 South Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 135 South Africa genome editing market, by application, 2018 - 2030 (USD Million)
Table 136 South Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 137 South Africa genome editing market, by mode, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia genome editing market, by technology, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia genome editing market, by application, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia genome editing market, by mode, 2018 - 2030 (USD Million)
Table 143 UAE genome editing market, by technology, 2018 - 2030 (USD Million)
Table 144 UAE genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 145 UAE genome editing market, by application, 2018 - 2030 (USD Million)
Table 146 UAE genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 147 Kuwait genome editing market, by technology, 2018 - 2030 (USD Million)
Table 148 Kuwait genome editing market, by delivery method, 2018 - 2030 (USD Million)
Table 149 Kuwait genome editing market, by application, 2018 - 2030 (USD Million)
Table 150 Kuwait genome editing market, by end-use, 2018 - 2030 (USD Million)
Table 151 Kuwait genome editing market, by mode, 2018 - 2030 (USD Million)

★調査レポート[世界のゲノム編集市場2023-2030：技術別（CRISPR、ZFN、TALEN）、送達方法別（エクスビボ、インビボ）、用途別、モード別、エンドユーザー別、地域別] (コード：GRV23JUN050)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のゲノム編集市場2023-2030：技術別（CRISPR、ZFN、TALEN）、送達方法別（エクスビボ、インビボ）、用途別、モード別、エンドユーザー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のゲノム編集及びゲノム工学市場予測2023-2029：CRISPR、TALEN、ZFN
  • 世界の遺伝子編集市場（～2028年）：製品＆サービス別（試薬、消耗品、システム、ソフトウェア）、技術別（CRISPR、TALEN、ZFN、アンチセンス）、用途別（細胞株工学、遺伝子工学、創薬）、エンドユーザー別（製薬、バイオテクノロジー）
  • 遺伝子編集のグローバル市場：CRISPR、TALEN、ZFN、アンチセンス、その他
  • 世界のELISA法分析器市場2023-2030：種類別（光学フィルター式ELISA法分析器、光学格子式ELISA法分析器）、モード別、用途別、エンドユーザー別、地域別
  • 世界のゲノム編集市場（～2030年）：エンドユーザー別（バイオテクノロジー＆製薬会社、学術＆研究機関、受託研究機関）、用途別（遺伝子工学、診断学、創薬＆開発）、技術別（CRISPR、TALEN、ZFN、アンチセンス）、オファリング別（試薬＆消耗品、ソフトウェア＆システム、サービス）
  • 世界の細胞＆遺伝子治療製造市場2023-2030：治療タイプ別、規模別（R&D）、モード別、ワークフロー別（ベクター生産、セルバンキング）、地域別
  • 世界の全ゲノムシーケンス（WGS）市場2023-2030：製品別（器具、消耗品、サービス）、種類別、ワークフロー別、用途別、エンドユーザー別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆